MYOSITIS

This study is testing whether adding a new type of immune cell therapy (called AlloNK) to an existing drug (rituximab) can better control several autoimmune diseases that have come back after standard treatments. The trial will enroll 90 adults with rheumatoid arthritis, Sjögren'…

This Phase 3 study is testing whether the investigational drug dazukibart can help control symptoms of dermatomyositis and polymyositis—rare autoimmune diseases that cause painful muscle inflammation and weakness. The trial will enroll 318 adults who are already taking standard m…

This early-stage study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease that haven't responded to standard therapies. The treatment uses genetically modified immune cells from healthy dono…

This study aims to understand if certain environmental factors, like infections, chemicals, or stressful events, might trigger a rare autoimmune disease that weakens muscles and can affect the lungs. Researchers will compare the past exposures of 580 people—including those with t…

This study aims to understand what research topics are most important to people living with rare inflammatory muscle diseases called myositis. Researchers will gather opinions from about 700 patients and caregivers worldwide through online surveys, stories, and group discussions.…

This study aims to create a large collection of blood samples and health information from people with autoimmune diseases like lupus and scleroderma. Researchers will use these samples to look for new biological markers that could help diagnose diseases earlier, predict how they …